315 citations
- E. Comets2 profiles4 · h 29
- M. Ursino4 · h 14
- S. Zohar2 profiles4 · h 31
- A. Cousien3 · h 13
- C. Burdet2 profiles3 · h 30
- F. Mentré2 profiles3 · h 65
- V. Tran2 profiles3 · h 19
- Y. Yazdanpanah3 profiles3 · h 74
- A. Andremont2 profiles2 · h 70
- F. Blanquart2 profiles2 · h 27
- Jean-Stéphane Dhersin2 · h 9
- J. Guedj2 · h 46
- InsermFR15 papers
- Sorbonne Paris CitéFR10 papers
- Assistance Publique – Hôpitaux de ParisFR9 papers
- Université Paris CitéFR9 papers
- Centre National de la Recherche ScientifiqueFR7 papers
- Université Paris DiderotFR7 papers
- Hôpital Bichat-Claude-BernardFR6 papers
- Sorbonne UniversitéFR6 papers
- Université de RennesFR4 papers
- Centre de Recherche des CordeliersFR3 papers
- Délégation Paris 7FR3 papers
- École des Hautes Études en Santé PubliqueFR3 papers
17 papers
In silico clinical trials in drug development: a systematic review
Bohua Chen, Lucia Chantal Schneider, Christian Röver +15
In the context of clinical research, computational models have received increasing attention over the past decades. In this systematic review, we aimed to provide an overview of th…
Straightforward Phase I Dose-Finding Design for Healthy Volunteers Accounting for Surrogate Activity Biomarkers
Sandrine Boulet, Emmanuelle Comets, Antoine Guillon +5
Conventionally, a first-in-human phase I trial in healthy volunteers aims to confirm the safety of a drug in humans. In such situations, volunteers should not suffer from any safet…
Bayesian Framework for Multi-Source Data Integration -- Application to Human Extrapolation From Preclinical Studies
Sandrine Boulet, Moreno Ursino, Robin Michelet +4
In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated befor…
The stochastic dynamics of early epidemics: probability of establishment, initial growth rate, and infection cluster size at first detection
Peter Czuppon, Emmanuel Schertzer, François Blanquart +1
Emerging epidemics and local infection clusters are initially prone to stochastic effects that can substantially impact the epidemic trajectory. While numerous studies are devoted…
The population-attributable fraction for time-dependent exposures and competing risks - A discussion on estimands
Maja von Cube, Martin Schumacher, Sebastien Bailly +5
The population-attributable fraction (PAF) quantifies the public health impact of a harmful exposure. Despite being a measure of significant importance an estimand accommodating co…
The population-attributable fraction for time-dependent exposures using dynamic prediction and landmarking
Maja von Cube, Martin Schumacher, Hein Putter +3
The public health impact of a harmful exposure can be quantified by the population-attributable fraction (PAF). The PAF describes the attributable risk due to an exposure and is of…